Pflaster statt Messer - neue Therapie des Basalioms mit 5-Fluorouracil?

Zusammenfassung

Das Basaliom ist der häufigste epitheliale Hauttumor des Menschen und wird zumeist chirurgisch behandelt. Wir stellen drei Kasuistiken zur lokalen Behandlung histologisch gesicherter Basaliome mit 5-Fluorouracil in einem transdermalen System vor, das täglich erneuert wird. Die Behandlung war sicher und effektiv, wie die Biopsien und die Kontrollen bis 6 Monate nach Therapieende zeigten. Eine Irritation der Haut trat nicht auf. Die kosmetischen Ergebnisse waren hervorragend. Daher haben wir eine klinische Studie geplant, um die Effekte des 5-Fluorouracil-Pflasters als neue Therapieoption für das Basaliom zu überprüfen.

Abstract

Basal cell carcinoma is the most frequent non-melanoma skin cancer in humans, treated mostly surgically. We present three case reports about topical application of 5-fluorouracil in a transdermal delivery system applied daily on histologically proven basal cell carcinomas. The treatment was safe and effective, shown by biopsies and follow-up for 6 months. Irritative effects were not seen. The cosmetic results were excellent. According to this, we will perform a controlled study to evaluate if 5-fluorouracil plaster might be a new treatment option for basal cell carcinoma.

Literatur

• 1 Bodde H E, Verhoeven J, van Driel L M. The skin compliance of transdermal drug delivery systems.  Crit Rev Ther Carrier Syst. 1989;  6 87-115
• 2 Bunney M H, Nolan M W, Williams D A. An assessment of methods of treating viral warts by comparison of treatment trials based on a standard design.  Br J Dermatol. 1976;  94 667-679
• 3 Cartei F, Carteil G, Girali T. et al . A phase II study of oral fluorouracil for gastrointestinal cancer.  Anticancer Drugs. 1996;  7 48-53
• 4 von Domarus H, Stevens P J. Metastatic basal cell carcinoma. Report of five cases and review of 170 cases in the literature.  J Am Acad Dermatol. 1984;  10 1043-1060
• 5 Ehrlich A, Henkerl-Ernst J, Schaefer A, Assmussen B, Lucker P W. Therapeutic delivery systems: a new approach to evaluate physical properties of transdermal delivery systems (TDS).  Methods Find Exp Clin Pharmacol. 1999;  21 69-71
• 6 Engelberg I S, Ronnen M, Suster S, Schewach-Millet M, Stempler D, Schibi-Brilliant G. Effects of Solcoderm.  Int J Dermatol. 1986;  25 606-607
• 7 Glorer E, Rzany B, Jung E G. Ausgedehnt exulzeriertes Basaliom. Behandlung mit ionisierender Strahlung nach elektrokaustischer Abtragung.  Hautarzt. 2001;  52 646-648
• 8 Graham G. Statistical data on malignant tumors in cryosurgery.  J Dermatol Surg Oncol. 1983;  9 238-239
• 9 Grunberg S M, Clay C, Spicer D V. Tolerance of extended (28 day) continuous infusion of 5-fluorouracil in advanced head and neck cancer.  Scl Cancer Ther. 1991;  7 17-21
• 10 Gupta A K, Weiss J S, Jorizzi J L. 5-fluorouracil 0,5 % cream for multiple actinic keratoses of the face and anterior scalp.  Skin Therapy Lett. 2001;  6 1-4
• 11 Holt P JA. Cyotherapy for skin cancer: results over a 5 year period using liquid nitrogen spray cryosurgery.  Br J Dermatol. 1988;  119 231-240
• 12 Kowalzick L, Rogozinski T, Schober C. et al . Treatment of basal cell carcinoma with intralesional recombinant interferon beta: a dose-finding study.  Eur J Dermatol. 1994;  4 430-433
• 13 Marks R, Gebauer K, Shumack S, Amies M, Bryden J, Fox T L, Owens M L. Imiquimod 5 % cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial.  J Am Acad Dermatol. 2001;  44 807-813
• 14 Merkle H P. Transdermal delivery systems.  Methods Find Exp Clin Pharmacol. 1989;  11 135-153
• 15 Miller B, Shavin J, Cognetta A. et al . Nonsurgical treatment of basal cell carcinomas with intralesional 5-fluorouracil/epinephrine injectable gel.  J Am Acad Dermatol. 1997;  36 72-77
• 16 Mohs F E. Chemosurgery for the microscopically controlled excision of skin cancer.  J Surg Oncol. 1971;  3 257-267
• 17 Niedner R. Transdermal therapeutic systems (TTS).  Hautarzt. 1988;  39 761-766
• 18 Orton C I. The treatment of basal cell carcinoma by radiotherapy.  Clin Oncol. 1978;  4 317-322
• 19 Peck G L. Topical tretinoin in actinic keratosis and basal cell carcinoma.  J Am Acad Dermatol. 1986;  15 829-835
• 20 Reyman F. Treatment of basal cell carcinoma of the skin with 5-fluorouracil ointment: a 10-year follow-up study.  Dermatologica. 1979;  158 368-372
• 21 Reyman F. 15 years' experience with treatment of basal cell carcinomas of the skin with curettage.  Acta Derm Venereol. 1985;  120 56-59
• 22 Romagosa R, Saap L, Givens M, Salvarrey A, He J L, Hsai S L, Taylor J R. A pilot study to evaluate the treatment of basal cell carcinoma with 5-fluorouracil using phosphatidyl choline as a transepidermal carrier.  Dermatol Surg. 2000;  26 338-340
• 23 Rowe D E, Caroll R J, Day C L Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up.  J Dermatol Surg Oncol. 1989;  15 315-328
• 24 Stenquist B, Wennberg A M, Gisslen H, Larko O. Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery.  J Am Acad Dermatol. 1992;  27 65-69
• 25 Stoll H L Jr, Klein E. Tumors of the skin. XI. Effect of occlusive dressing on the local administration of 5-fluorouracil to superficial basal cell carcinoma.  J Invest Dermatol. 1969;  52 304-306
• 26 Thissen M, Neumann M, Schouten L. A systematic review of treatment modalities for primary basal cell carcinomas.  Arch Dermatol. 1999;  135 1177-1183
• 27 Wang I, Bendsoe N, Klintenberg C AF, Enejder A M, Andersson-Engels S, Svanberg S, Svanberg K. Photodynamic therapy versus cryosurgery of basal cell carcinoma: results of a phase III clinical trial.  Br J Dermatol. 2001;  144 832-840
• 28 Whelan C, Deckers P. Electrocoagulation for skin cancer: an old oncologic tool revisted.  Cancer. 1981;  47 2280-2287
• 29 Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratose, superficial squamous cell carcinomas and basal cell carcinomas?.  J Am Acad Dermatol. 1993;  28 17-21